行情

ICPT

ICPT

Intercept制药
NASDAQ

实时行情|Nasdaq Last Sale

15.10
-0.08
-0.53%
盘后: 15.10 0 0.00% 16:43 09/21 EDT
开盘
15.34
昨收
15.18
最高
15.50
最低
14.42
成交量
104.14万
成交额
--
52周最高
43.16
52周最低
11.60
市值
5.01亿
市盈率(TTM)
-2.9328
分时
5日
1月
3月
1年
5年
Intercept 将出席 2021 年 Cantor 虚拟全球医疗保健会议
Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief Executive...
GlobeNewswire · 15小时前
Intercept Pharmaceuticals 将回购 3990 万美元的可转换票据
MT Newswires · 09/13 15:55
Intercept Pharmaceuticals 宣布回购可转换票据
NEW YORK, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, ann...
GlobeNewswire · 09/13 12:00
分析师为今年秋季的小型生物科技股(INMB、DVAX、SAVA、ICPT、IMGN、ATRX)提供理由
WallStreetPR · 09/09 11:07
Intercept 将出席 Virtual Baird 2021 全球医疗保健会议
NEW YORK, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced th...
GlobeNewswire · 09/01 12:00
从周五开始的 58 个最大的推动者
Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares climbed 204.1% to close at $19.16 on Friday. Regencell Bioscience reported partial exercise of underwriter’s over-allotment option.
Benzinga · 08/23 09:06
Intercept Pharma 股票下跌,因高盛减持
Intercept Pharma shares traded lower after Goldman Sachs downgraded the stock to sell and lowered its price target to $10 from $17.
TheStreet.com · 08/20 14:30
高盛下调评级后 Intercept Pharmaceuticals 股价下跌
MT Newswires · 08/20 14:05
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解ICPT最新的财务预测,通过ICPT每股收益,每股净资产,每股现金流等数据分析Intercept制药近期的经营情况,然后做出明智的投资选择。
分析师评级

19位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测ICPT价格均价为31.63,最高价位82.00,最低价为10.00。
EPS
机构持股
总机构数: 276
机构持股: 2,388.06万
持股比例: 71.93%
总股本: 3,320.12万
类型机构数股数
增持
53
199.51万
建仓
14
37.26万
减持
30
424.74万
平仓
35
65.52万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+1.43%
制药与医学研究
+0.74%
高管信息
Non-Executive Chairman/Independent Director
Paolo Fundaro
President/Chief Executive Officer/Chief Operating Officer/Director
Jerome Durso
Chief Financial Officer
Andrew Saik
Corporate Executive
Lisa Bright
Chief Human Resource Officer
David Ford
Executive Vice President
Linda Richardson
Executive Vice President
Christian Weyer
Senior Vice President
Gail Cawkwell
Senior Vice President
Lisa DeFrancesco
Chief Accounting Officer/Controller
Rocco Venezia
Lead Director/Independent Director
Gino Santini
Independent Director
Srinivas Akkaraju
Independent Director
Luca Benatti
Independent Director
Daniel Bradbury
Independent Director
Keith Gottesdiener
Independent Director
Nancy Miller-Rich
Independent Director
Dagmar Rosa-bjorkeson
Independent Director
Glenn Sblendorio
暂无数据
ICPT 简况
Intercept Pharmaceuticals, Inc.是一家生物制药公司。该公司专注于开发及商业化用于治疗非病毒性慢性肝病的药品。该公司的候选产品有潜力治愈难治疗的罕见病及流行病。其候选产品奥贝胆酸(OCA)是胆汁酸类似物,是一种拥有类似于自然产生的人体胆汁酸结构的化学物质。该胆汁酸选择性活化法呢醇X受体。该公司正在开发用于治疗肝病的OCA,如:原发性胆汁性肝硬化(PBC)、非酒精性脂肪性肝炎(NASH)、原发性硬化性胆管炎(PCS)以及胆管闭锁。该公司还开发其他产品,包括:用于治疗纤维变性的INT-767以及用于治疗二型糖尿病的INT-777。

微牛提供Intercept Pharmaceuticals Inc(NASDAQ-ICPT)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的ICPT股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ICPT股票基本功能。